Hyperphagia
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with Prader-Willi syndrome, Soleno Therapeutics announced.
Setmelanotide reduces hyperphagia, improves quality of life in Bardet-Biedl syndrome
Treatment with the melanocortin-4 receptor agonist setmelanotide reduced hyperphagia and led to improvements in emotional well-being among children and adults with Bardet-Biedl syndrome, according to study findings.
FDA rejects new drug application for internasal carbetocin to treat Prader-Willi syndrome
The FDA’s Division of Psychiatry has rejected a new drug application for treating hyperphagia, anxiousness and distress associated with Prader-Willi syndrome, according to a press release.
FDA grants priority review for intranasal Prader-Willi syndrome therapy
The FDA granted priority review for a new drug application for an intranasal oxytocin analogue to reduce hyperphagia and behavioral distress associated with Prader-Willi syndrome, according to an industry press release.
CARE-PWS: Intranasal oxytocin analogue reduces hyperphagia in Prader-Willi syndrome
Adults with Prader-Willi syndrome who received an intranasal oxytocin analogue for 8 weeks reported a significant reduction in hyperphagia and symptoms of anxiety and distress, according to topline results of the CARE-PWS study.
Rare obesity disorders call for genetic testing, targeted therapies
Severe obesity starting early in life is a hallmark of rare genetic disorders of obesity. A genetic diagnosis can alleviate feelings of guilt or blame and lessen social stigma for youths with these disorders and their families.
Positive top-line findings announced for congenital obesity drug
Rhythm Pharmaceuticals announced positive results from two phase 3 clinical trials evaluating setmelanotide, a melanocortin-4 receptor agonist for the treatment of rare congenital forms of obesity, according to a company press release.